Abstract:ObjectivesTo assess the value of hepatospecific MR contrast agent uptake on hepatobiliary phase (HBP) images to detect marked activation of the β-catenin pathway in hepatocellular adenomas (HCAs).MethodsThis multicentric retrospective IRB-approved study included all patients with a pathologically proven HCA who underwent gadobenate dimeglumine–enhanced liver MRI with HBP. Tumor signal intensity on HBP was first assessed visually, and lesions were classified into three distinct groups—hypointense, isointense, or hyperintense—according to the relative signal intensity to liver. Uptake was then quantified using the lesion-to-liver contrast enhancement ratio (LLCER). Finally, the accuracy of HBP analysis in depicting marked β-catenin activation in HCA was evaluated.ResultsA total of 124 HCAs were analyzed including 12 with marked β-catenin activation (HCA B+). Visual analysis classified 94/124 (76%), 12/124 (10%), and 18/124 (14%) HCAs as being hypointense, isointense, and hyperintense on HBP, respectively. Of these, 1/94 (1%), 3/12 (25%), and 8/18 (44%) were HCA B+, respectively (p < 0.001). The LLCER of HCA B+ was higher than that of HCA without marked β-catenin activation in the entire cohort (means 4.9 ± 11.8% vs. − 19.8 ± 11.4%, respectively, p < 0.001). A positive LLCER, i.e., LLCER ≥ 0%, had 75% (95% CI 43–95%) sensitivity and 97% (95% CI 92–99%) specificity, with a LR+ of 28 (95% CI 8.8–89.6) for the diagnosis of HCA B+.ConclusionsHepatospecific contrast uptake on hepatobiliary phase is strongly associated with marked activation of the β-catenin pathway in hepatocellular adenoma, and its use might improve hepatocellular adenoma subtyping on MRI.Key Points• Tumor uptake on hepatobiliary phase in both the visual and quantitative analyses had a specificity higher than 90% for the detection of marked β-catenin activation in hepatocellular adenoma.• However, the sensitivity of visual analysis alone is inferior to that of LLCER quantification on HBP due to the high number of HCAs with signal hyperintensity on HBP, especially those developed on underlying liver steatosis.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to evaluate the value of the uptake of liver - specific MRI contrast agents on hepatobiliary phase images in detecting significantly activated β - catenin pathways in hepatocellular adenoma (HCA). Specifically, the study aims to evaluate whether this contrast agent uptake is related to significant β - catenin activation in HCA through visual and quantitative analyses, and to explore its potential to improve HCA classification on MRI. ### Research Background - **Hepatocellular Adenoma (HCA)**: This is a rare benign liver tumor, mainly occurring in young women taking oral contraceptives. The main complications of HCA are tumor bleeding and malignant transformation, which may require liver resection. - **β - catenin Activation**: There is β - catenin activation in HCA. In particular, when exon 3 of β - catenin is mutated or deleted, it significantly increases the risk of HCA malignantly transforming into hepatocellular carcinoma (HCC). - **Imaging Features**: Typical HCA shows low signal intensity after administration of liver - specific MRI contrast agents because the expression of organic anion - transporting polypeptides (OATP) in these tumors is reduced. However, some studies have shown that OATP expression still exists in β - catenin - activated HCA, which may cause these tumors to show iso - or high - signal on hepatobiliary phase (HBP) images. ### Research Objectives - **Evaluating Liver - Specific MRI Contrast Agent Uptake**: The study evaluates the value of contrast agent uptake on hepatobiliary phase images in detecting significant β - catenin activation in HCA through visual and quantitative analyses. - **Improving the Accuracy of HCA Classification**: To explore whether contrast agent uptake on hepatobiliary phase images can be a useful tool for HCA subtype classification, especially in detecting HCA with significant β - catenin activation. ### Methods - **Patient Population**: MRI data of 85 pathologically - diagnosed HCA patients were retrospectively studied. - **Imaging Technique**: Liver - specific contrast agent (gadobenate dimeglumine) - enhanced MRI examinations were performed using 1.5T and 3.0T MRI scanners. - **Visual Analysis**: Two radiologists visually evaluated the hepatobiliary phase images and classified the lesions as low - signal, iso - signal, and high - signal. - **Quantitative Analysis**: The lesion - to - liver contrast - enhancement ratio (LLCER) was calculated to evaluate the quantitative index of contrast agent uptake. ### Results - **Visual Analysis**: 94/124 (76%) of HCA showed low - signal, 12/124 (10%) were iso - signal, and 18/124 (14%) were high - signal. Among them, 1/94 (1%), 3/12 (25%), and 8/18 (44%) were HCA B+ (significant β - catenin activation). - **Quantitative Analysis**: The LLCER value of HCA B+ was significantly higher than that of HCA without significant β - catenin activation (the means were 4.9 ± 11.8% and - 19.8 ± 11.4% respectively, p < 0.001). The sensitivity of LLCER ≥ 0% was 75% (95% CI 43 - 95%), the specificity was 97% (95% CI 92 - 99%), and the positive likelihood ratio was 28 (95% CI 8.8 - 89.6). ### Conclusions - **Liver - Specific Contrast Agent Uptake is Related to Significant β - catenin Activation**: Contrast agent uptake on hepatobiliary phase images is strongly related to significant β - catenin activation in HCA, which helps to improve the MRI classification of HCA. - **Quantitative Analysis is Superior to Visual Analysis**: Although visual analysis has high specificity in detecting significant β - catenin activation, its sensitivity is low. Quantitative analysis (LLCER) can more accurately reflect the uptake situation of the tumor, thereby improving the accuracy of diagnosis. ### Key Points - **Tumor Uptake on Hepatobiliary Phase Images**: In both visual and quantitative analyses, tumor uptake on hepatobiliary phase images has more than 90% specificity in detecting significant β - catenin activation in HCA. - **The Importance of Quantitative Analysis**: The use of LLCER can make up for the lack of sensitivity in visual analysis and improve the accuracy of HCA classification.

Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma

[Application Value of Contrast-Enhanced Ultrasonography for Assessing the High-Risk Population of Hepatic Malignant Tumor].

Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping

HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI

Beta‐Catenin‐Mutated Hepatocellular Adenomas at Hepatobiliary Phase MRI: A Systematic Review and Meta‐Analysis

Analysis of Contrast-Enhanced Ultrasound Features of Hepatocellular Adenoma According to Different Pathological Molecular Classifications.

Qualitative and Quantitative Gadoxetic Acid-enhanced MR Imaging Helps Subtype Hepatocellular Adenomas.

Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT

Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma

OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy

Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation?

Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI

Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions

Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?

MRI for characterization of benign hepatocellular tumors on hepatobiliary phase: the added value of in-phase imaging and lesion-to-liver visual signal intensity ratio

Preoperative radiomics model using gadobenate dimeglumine-enhanced magnetic resonance imaging for predicting β-catenin mutation in patients with hepatocellular carcinoma: A retrospective study

Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review

Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification

Subtyping of hepatocellular adenomas using Gd-EOB-DTPA: a qualitative and quantitative analysis

Diagnostic Value of Gd-EOB-DTPA-MRI for Hepatocellular Adenoma: A Meta-Analysis

A case of β-catenin-positive hepatocellular adenoma with MR imaging sign of diffuse intratumoral fat deposition